Zydus Lifesciences Limited — Updates, 12-08-2025: Press Release

Zydus Lifesciences reported Q1 FY26 consolidated revenues of ₹6,573.7 Cr, up 6% YoY. Net Profit increased 3% to ₹1,466.8 Cr, while EBITDA was flat at ₹2,088.5 Cr. R&D investments stood at ₹485.6 Cr. Key growth drivers included International Markets (up 37%) and India Formulations (up 8%). The US FDA issued Establishment Inspection Reports for two API facilities. The company is advancing its innovation pipeline with Phase II(b) ALS trials and biosimilar approvals. Strategic moves include acquiring Agenus's US biologics manufacturing and a stake in Amplitude Surgical SA, marking a foray into CDMO and MedTech.